TALPHERA, INC. — Director's Dealing 2022

Feb 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2022-02-11

Reporting Person: Palmer Pamela P (Director, Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-11	Common Stock	A	122500	$0.00	Acquired	785111	Direct
2022-02-11	Common Stock	F	7927	$0.4014	Disposed	777184	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-11	Stock Option (Right to Buy)	$0.4014	A	245000	Acquired	2032-02-11	Common Stock (245000)	Direct

Footnotes

F1: The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2023, February 11, 2024 and February 11, 2025.

F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

F3: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.

F4: On February 11, 2022, the reporting person was granted an option to purchase 245,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.